Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide for Actinic Keratosis Prevention in Kidney Transplant Recipients
NCT04843553Phase 1Completed
- Sponsor
- Rhode Island Hospital
- Start
- Oct 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in actinic keratosis (AK) and non-melanoma skin cancer (NMSC) comparing Nicotinamide Arm with Placebo Arm (2 arms). Primary endpoint: Total number of actinic keratoses at 12 months. Started Oct 2016; status: completed.
02
Drugs
nicotinamide
03
Conditions
actinic keratosis (AK)non-melanoma skin cancer (NMSC)
Beyond the preview
Go deeper on NCT04843553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04843553.